全文获取类型
收费全文 | 2167篇 |
免费 | 146篇 |
国内免费 | 9篇 |
专业分类
耳鼻咽喉 | 28篇 |
儿科学 | 46篇 |
妇产科学 | 61篇 |
基础医学 | 266篇 |
口腔科学 | 119篇 |
临床医学 | 231篇 |
内科学 | 454篇 |
皮肤病学 | 41篇 |
神经病学 | 162篇 |
特种医学 | 63篇 |
外科学 | 269篇 |
综合类 | 8篇 |
一般理论 | 1篇 |
预防医学 | 209篇 |
眼科学 | 29篇 |
药学 | 166篇 |
中国医学 | 14篇 |
肿瘤学 | 155篇 |
出版年
2024年 | 7篇 |
2023年 | 29篇 |
2022年 | 78篇 |
2021年 | 122篇 |
2020年 | 76篇 |
2019年 | 93篇 |
2018年 | 97篇 |
2017年 | 70篇 |
2016年 | 88篇 |
2015年 | 91篇 |
2014年 | 120篇 |
2013年 | 139篇 |
2012年 | 190篇 |
2011年 | 189篇 |
2010年 | 105篇 |
2009年 | 77篇 |
2008年 | 130篇 |
2007年 | 123篇 |
2006年 | 105篇 |
2005年 | 107篇 |
2004年 | 100篇 |
2003年 | 71篇 |
2002年 | 54篇 |
2001年 | 4篇 |
2000年 | 1篇 |
1999年 | 8篇 |
1998年 | 3篇 |
1997年 | 2篇 |
1996年 | 5篇 |
1995年 | 6篇 |
1992年 | 3篇 |
1991年 | 4篇 |
1988年 | 2篇 |
1985年 | 3篇 |
1984年 | 2篇 |
1983年 | 3篇 |
1982年 | 1篇 |
1981年 | 2篇 |
1980年 | 2篇 |
1978年 | 2篇 |
1977年 | 1篇 |
1975年 | 1篇 |
1974年 | 2篇 |
1973年 | 1篇 |
1969年 | 2篇 |
1962年 | 1篇 |
排序方式: 共有2322条查询结果,搜索用时 15 毫秒
31.
Santos Camila Leite Bobermin Larissa Daniele Souza Diogo Onofre Quincozes-Santos André 《Metabolic brain disease》2018,33(6):2059-2063
Metabolic Brain Disease - Leptin is an adipose tissue-derived hormone that acts on the hypothalamus in order to maintain energy homeostasis. However, leptin can also induce an inflammatory... 相似文献
32.
33.
34.
Brandon P. Verdoorn MD Tamara K. Evans BS Gregory J. Hanson MD Yi Zhu PhD Larissa G. P. Langhi Prata PhD Robert J. Pignolo MD PhD Elizabeth J. Atkinson MS Erin O. Wissler-Gerdes MA George A. Kuchel MD Joan B. Mannick MD Stephen B. Kritchevsky PhD Sundeep Khosla MD Stacey A. Rizza MD Jeremy D. Walston MD Nicolas Musi MD Lewis A. Lipsitz MD Douglas P. Kiel MD Raymond Yung MB ChB Nathan K. LeBrasseur PhD Ravinder J. Singh PhD Teresa McCarthy MD MS Michael A. Puskarich MD Laura J. Niedernhofer MD PhD Paul D. Robbins PhD Matthew Sorenson JD MA Tamara Tchkonia PhD James L. Kirkland MD PhD 《Journal of the American Geriatrics Society》2021,69(11):3023-3033
The burden of senescent cells (SnCs), which do not divide but are metabolically active and resistant to death by apoptosis, is increased in older adults and those with chronic diseases. These individuals are also at the greatest risk for morbidity and mortality from SARS-CoV-2 infection. SARS-CoV-2 complications include cytokine storm and multiorgan failure mediated by the same factors as often produced by SnCs through their senescence-associated secretory phenotype (SASP). The SASP can be amplified by infection-related pathogen-associated molecular profile factors. Senolytic agents, such as Fisetin, selectively eliminate SnCs and delay, prevent, or alleviate multiple disorders in aged experimental animals and animal models of human chronic diseases, including obesity, diabetes, and respiratory diseases. Senolytics are now in clinical trials for multiple conditions linked to SnCs, including frailty; obesity/diabetes; osteoporosis; and cardiovascular, kidney, and lung diseases, which are also risk factors for SARS-CoV-2 morbidity and mortality. A clinical trial is underway to test if senolytics decrease SARS-CoV-2 progression and morbidity in hospitalized older adults. We describe here a National Institutes of Health-funded, multicenter, placebo-controlled clinical trial of Fisetin for older adult skilled nursing facility (SNF) residents who have been, or become, SARS-CoV-2 rtPCR-positive, including the rationale for targeting fundamental aging mechanisms in such patients. We consider logistic challenges of conducting trials in long-term care settings in the SARS-CoV-2 era, including restricted access, consent procedures, methods for obtaining biospecimens and clinical data, staffing, investigational product administration issues, and potential solutions for these challenges. We propose developing a national network of SNFs engaged in interventional clinical trials. 相似文献
35.
Larissa K. Laskowski Faesal Elbakoush Jessica Calvo Gina Exantus-Bernard Jane Fong Justin L. Poklis Alphonse Poklis Lewis S. Nelson 《Journal of medical toxicology》2015,11(2):237-241
Introduction
The NBOMes (N-benzyl-oxy-methyl derivatives of known 2C phenylethylamines) are a new and growing class of potent synthetic stimulants. Case reports provide the bulk of available safety and clinical data for clinicians. We report two cases of NBOMe intoxication with 25C-NBOMe (the first lab-confirmed US case) and 25B-NBOMe, respectively, both confirmed via triple quadrapole mass spectrometry.Case Reports
Case 1: A 16-year-old girl had a generalized seizure after reported use of 25I-NBOMe. She presented with altered mental status, lower extremity rigidity, and elevated CPK (6042 U/L). Despite treatment with benzodiazepines, her lower extremity rigidity persisted and CPK peaked at 47,906 U/L. She was discharged on hospital day 8. Serum and urine specimens confirmed presence of 25C-NBOMe. Case 2: A 15-year-old boy developed bizarre behavior after reported use of 25I-NBOMe. In the ED, he had two generalized seizures and persistent muscle rigidity. CPK peaked at 429 U/L. Seizures were managed with benzodiazepines, and he was discharged within 24 h. Serum specimens revealed 25B-NBOMe.Discussion
NBOMes are amphetamine derivatives and highly potent 5-HT2A receptor agonists. Clinical manifestations are a product of enhanced central sympathetic and serotonergic tone. We report two cases of NBOMe intoxication in patients who believed they used 25I-NBOME, while lab confirmation proved otherwise. Whether unique clinical manifestations are specific to the NBOMe variant, dose, route of administration, or other factors is unknown. Laboratory confirmation may play a role in identifying unexpected NBOMe variants, while contributing to the epidemiologic data on these novel substances. 相似文献36.
Elizabeth L. Pestka Julia Craner Michele Evans Virginia Nash Njoki Kimondo Deborah Pestka Larissa Loukianova Jeannie Sperry 《Pain Management Nursing》2018,19(2):115-124
The objectives of this study were to examine association between a family history of substance abuse and admission morphine equivalent dose, depression and pain catastrophizing screening scores, as well as reported personal history of substance use. The retrospective research was completed in an interdisciplinary three-week pain rehabilitation center. The subject cohort included admissions from January through December 2014 with 351 datasets for family history of substance abuse and oral morphine equivalency and 341 for depression, pain catastrophizing and use of substances. Outcome measures included admission self-reported data on family history of substance abuse and past and current substance use, admission morphine equivalency dose, and scores on the Center for Epidemiologic Studies-Depression Scale and the Pain Catastrophizing Scale. One hundred forty-seven patients were using opioid medications on admission and those with a positive family history of substance abuse had an oral morphine equivalency (M = 92.12, SD = 95.32) compared to a negative history (M = 80.34, SD = 64.86); the difference was not statistically significant, t (120.01) =.87, p = .39. Patients with a positive family history reported higher levels of both depression, t (327.40) = 3.15, p = .002 and pain catastrophizing, t (338) = 2.76, p = .01. Those with a positive family history endorsed greater frequency of past alcohol use χ2 (1, N = 326) = 6.67, p = 0.1 and marijuana use χ2 (1, N = 341) = 4.23, p = .04 and past χ2 (1, N = 329) = 9.90, p = .002 and current tobacco use χ2 (1, N = 327) = 8.81, p = .003. Use of family history of substance abuse information may help provide data for multimodal treatments of chronic non-cancer-pain. The findings from this study can be used to guide future research. 相似文献
37.
38.
Ana Carolina G. Zanetti Tais Milena Pantaleão de Souza Larissa de Souza Tressoldi João Mazzoncini de Azevedo-Marques Gabriel Elias Corrêa-Oliveira Amanda Heloisa Santana da Silva Isabela dos Santos Martin Kelly Graziani Giacchero Vedana Lucilene Cardoso Sueli Aparecida Frari Galera Edilaine Cristina da Silva Gherardi-Donato 《Archives of Psychiatric Nursing》2018,32(3):390-395
BACKGROUND
Evidence suggests that expressed emotion (EE) and family burden (FB) are phenomena that interact, but there is a lack of studies that analyze this association in patients in first-episode psychosis.AIM
This study evaluated the relationship between EE and FB in relatives of patients in first-episode psychosis.METHOD
A convenience sample of 71 family members of patients being assisted in an outpatient care unit participated in the study. We used a form with sociodemographic and clinical variables of family members and patients, the Family Questionnaire-Brazilian Portuguese Version and the Brazilian version of the Burden Interview. The data were obtained via semi-structured interviews. Statistical analyses included Fisher's exact tests, Mann Whitney tests, Spearman correlations, and Student's t-tests.RESULTS
Our results showed high levels of EE and its component emotional over-involvement (EOI) among relatives, and a strong correlation between critical comments (CC) and EOI and FB measurements. In addition, family members with elevated EE levels showed higher means for FB and this difference was significant.CONCLUSIONS
Mental health nurses are expected to consider these concepts for proposing nursing interventions to first-episode psychosis patients and their relatives. 相似文献39.
Viskoper R Shapira I Priluck R Mindlin R Chornia L Laszt A Dicker D Gavish B Alter A 《American journal of hypertension》2003,16(6):484-487
BACKGROUND: Recent studies have demonstrated the antihypertensive effect of slow breathing exercises, guided interactively by a device, in patients with uncontrolled blood pressure (BP) without changing medication. This study examined the response to the same treatment protocol in resistant hypertensives. METHODS: Seventeen resistant hypertensives exercised device-guided slow breathing for 8 weeks, 15 min daily, and self-monitored BP. Data stored in the devices were collected on a PC-based system. Clinical outcomes were office and home BP changes from baseline to end values. RESULTS: Significant reductions in both office BP (-12.9/-6.9 mm Hg, P <.001 and home BP (-6.4/-2.6 mm Hg, P <.01/P <.05) without side effects with 82% responders and good compliance. CONCLUSIONS: Resistant hypertensives can benefit from and are compliant with self-treatment by device-guided slow breathing. 相似文献
40.
Interferon-alpha,but not the ABL-kinase inhibitor imatinib (STI571), induces expression of myeloblastin and a specific T-cell response in chronic myeloid leukemia 总被引:5,自引:5,他引:5 下载免费PDF全文